Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (t-cells) | 0.10 |
| chemistry Open Targets | reachable by antibody: zolimomab aritox | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 8 Parkinson's papers of 8,014 | 0.71 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 6444
Sealed predictions
- CD5 in dopamine neurons, braak-0.30 (p 0.428) → -0.82 (p 0.007)receipt 6451
Swarm cases
receipt 6451: CD5 in dopamine neurons, braak
- power
- full sample -0.29 (p 0.235, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.29 (p 0.246, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.39 (p 0.105, n 18). could be the mix.
- skeptic
- leave-one-out range -0.41 to -0.20, sign flips 0; without severely affected donors -0.29 (p 0.235, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD5 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts